Survival Outcome of Empirical Antifungal Therapy and the Value of Early Initiation: A Review of the Last Decade

dc.contributor.authorKanj, Souha S.
dc.contributor.authorOmrani, Ali S.
dc.contributor.authorAl-Abdely, Hail Mater
dc.contributor.authorSubhi, Ahmad
dc.contributor.authorEl-Fakih, Riad Omar
dc.contributor.authorAbosoudah, Ibraheem Faisal
dc.contributor.authorKanj, Hazar
dc.contributor.authorDimopoulos, George T.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentDivision of Infectious Diseases
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:44:10Z
dc.date.available2025-01-24T11:44:10Z
dc.date.issued2022
dc.description.abstractAim: This rapid systematic review aimed to collect the evidence published over the last decade on the effect of empirical antifungal therapy and its early initiation on survival rates. Methods: A systematic search was conducted in PubMed, Cochrane, Medline, Scopus, and Embase, in addition to a hand search and experts’ suggestions. Results: Fourteen cohort studies and two randomized clinical trials reporting the survival outcome of empirical antifungal therapy were included in this review. Two studies reported the association between early empirical antifungal therapy (EAFT) and survival rates in a hematological cancer setting, and fourteen studies reported the outcome in patients in intensive care units (ICU). Six studies reported that appropriate EAFT decreases hospital mortality significantly; ten studies could not demonstrate a statistically significant association with mortality rates. Discussion: The inconsistency of the results in the literature can be attributed to the studies’ small sample size and their heterogeneity. Many patients who may potentially benefit from such strategies were excluded from these studies. Conclusion: While EAFT is practiced in many settings, current evidence is conflicting, and high-quality studies are needed to demonstrate the true value of this approach. Meanwhile, insights from experts in the field can help guide clinicians to initiate EAFT when indicated. © 2022 by the authors.
dc.identifier.doihttps://doi.org/10.3390/jof8111146
dc.identifier.eid2-s2.0-85141760801
dc.identifier.urihttp://hdl.handle.net/10938/30411
dc.language.isoen
dc.publisherMDPI
dc.relation.ispartofJournal of Fungi
dc.sourceScopus
dc.subjectAntifungal agents
dc.subjectEmpirical therapy
dc.subjectIntensive care
dc.subjectInvasive aspergillosis
dc.subjectInvasive candidiasis
dc.titleSurvival Outcome of Empirical Antifungal Therapy and the Value of Early Initiation: A Review of the Last Decade
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2022-1489.pdf
Size:
3.61 MB
Format:
Adobe Portable Document Format